Eli Lilly’s Weekly Insulin Efsitora Alfa Matches Daily Basal Insulins in Reducing A1C Levels
Eli Lilly and Company (NYSE: LLY), a global healthcare company, has announced results from a...
Drug
Biotherus Inc. Advances PM8002 Bispecific Antibody to Phase III for Triple Negative Breast Cancer
China’s Biotheus Inc. has announced the initiation of a Phase III clinical study for its...
Jiangsu Hengrui’s Camrelizumab/Apatinib Combo Denied FDA Approval Over Manufacturing Issues
The US Food and Drug Administration (FDA) has issued a complete response letter to Jiangsu...
ImmuneOnco Biopharmaceuticals’ CD47 Inhibitor Receives NMPA Go-Ahead for Phase III Trial
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd has announced that it has received approval from the National...
CSPC Pharmaceutical’s βKlotho Monoclonal Antibody JMT202 Receives Clinical Trial Approval from NMPA
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced...
Roche’s CT-388 Shows Significant Weight Loss in Phase I Clinical Trial for Obesity
Switzerland-based healthcare giant Roche (SWX: ROG) has announced preliminary results from a Phase I study...
Eisai to Support Grassroots Healthcare in China with Significant Pariet Donation
Eisai (TYO: 4523), a leading Japanese pharmaceutical company, has announced its commitment to donate 100,000...
North China Pharmaceutical’s Ormutivimab Approved for Pediatric Use in China
North China Pharmaceutical Group Corporation (SHA: 600812) has announced that it has received approval from...
HutchMed’s Sovleplenib Phase III Results to be Showcased at EHA 2024
HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013), a biopharmaceutical company based in China, is preparing...
Shanghai UniCAR-Therapy’s Innovative CAR-T Therapy Targets Breakthrough Designation with IL-6 Silencing
Shanghai UniCAR-Therapy Bio-Medicine Technology Co., Ltd, a leading biopharmaceutical company based in China, is on...
Bayer’s 225Ac-PSMA-Trillium Therapy Begins Early-Stage Clinical Trial for mCRPC
Bayer AG (ETR: BAYN), a multinational pharmaceutical company based in Germany, has this week commenced...
Roc Rock Biotechnology Secures Ethical Approval for CAR-M Therapy in Ovarian Cancer
China-based Roc Rock Biotechnology Co., Ltd. has announced that it has received ethical approval from...
Olymvax Biopharmaceuticals Gets Green Light for Tetravalent Influenza Vaccine Clinical Trial
Olymvax Biopharmaceuticals Inc. (SHA: 688319), a leading vaccine specialist headquartered in Chengdu, China, has announced...
Insilico Medicine’s ISM8207 Enters Phase I Clinical Trial for Lymphoma and Solid Tumors
China’s generative artificial intelligence (AI)-driven biotech firm, Insilico Medicine, has announced the first patient dosing...
Everest Medicines Commences Commercial Sales of Nefecon in China Post-Launch
Everest Medicines (HKG: 1952), a leading pharmaceutical company based in China, has announced the official...
Fosun Pharmaceutical Advances Lasofocine Clinical Trials for Breast Cancer after NMPA Nod
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that it has...
Zai Lab Advances Vygart Hytrulo for CIDP with sBLA Filing in China
Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688), a biopharmaceutical company based in China, has announced...
Jiangsu Hengrui’s SHR-2173 Gets Green Light for Clinical Trial in IgA Nephropathy
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...
ViiV Healthcare’s HIV-PreP Therapy Approved by China’s NMPA, Offers Alternative to Daily Medication
GlaxoSmithKline’s (GSK; NYSE: GSK) subsidiary, ViiV Healthcare, has announced that it has received marketing approvals...
Tonghua Dongbao Pharmaceuticals Begins Clinical Trial for Xultophy Biosimilar
Tonghua Dongbao Pharmaceuticals (SHA: 600867), a Chinese pharmaceutical company, has announced the dosing of the...